Third Harmonic Bio Future Growth

Future criteria checks 0/6

Third Harmonic Bio's earnings are forecast to decline at 28.4% per annum. EPS is expected to decline by 20.4% per annum.

Key information

-28.4%

Earnings growth rate

-20.4%

EPS growth rate

Pharmaceuticals earnings growth	23.7%
Revenue growth rate	n/a
Future return on equity	-29.7%
Analyst coverage	Low
Last updated	11 Nov 2024

Recent future growth updates

No updates

Recent updates

Third Harmonic Bio (NASDAQ:THRD) Is In A Good Position To Deliver On Growth Plans

Nov 16

Companies Like Third Harmonic Bio (NASDAQ:THRD) Can Afford To Invest In Growth

Aug 03

Here's Why We're Not At All Concerned With Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Situation

Apr 06

Earnings and Revenue Growth Forecasts

NasdaqGM:THRD - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-101	-65	-72	2
12/31/2025	N/A	-68	-64	-61	4
12/31/2024	N/A	-48	-36	-36	4
9/30/2024	N/A	-39	-29	-29	N/A
6/30/2024	N/A	-33	-25	-25	N/A
3/31/2024	N/A	-30	-20	-20	N/A
12/31/2023	N/A	-31	-21	-20	N/A
9/30/2023	N/A	-35	-24	-24	N/A
6/30/2023	N/A	-36	-31	-31	N/A
3/31/2023	N/A	-36	-34	-33	N/A
12/31/2022	N/A	-35	-35	-35	N/A
9/30/2022	N/A	-39	-30	-30	N/A
6/30/2022	N/A	-39	-23	-23	N/A
3/31/2022	N/A	-34	-20	-20	N/A
12/31/2021	N/A	-30	-16	-16	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: THRD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: THRD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: THRD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if THRD's revenue is forecast to grow faster than the US market.

Third Harmonic Bio Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Third Harmonic Bio (NASDAQ:THRD) Is In A Good Position To Deliver On Growth Plans

Companies Like Third Harmonic Bio (NASDAQ:THRD) Can Afford To Invest In Growth

Third Harmonic Bio, Inc. Announce Resignation of Rob Perez as a Class I Director of the Board, and as Chairperson of the Nominating and Governance Committee of the Board and A Member of the Audit Committee of the Board

Chief Development Operations Officer notifies of intention to sell stock

Third Harmonic Bio, Inc. Announces the Appointment and Promotion of Key Executive Leaders to the Organization

Third Harmonic Bio, Inc., Annual General Meeting, Jun 06, 2024

CEO & Director notifies of intention to sell stock

Here's Why We're Not At All Concerned With Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Situation

High number of new directors

Third Harmonic Bio, Inc. Appoints Geoff Mcdonough to Its Board of Directors

Chief Administrative Officer notifies of intention to sell stock

Third Harmonic Bio, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective November 10, 2023

We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely

Third Harmonic Bio, Inc Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335

We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely

Third Harmonic Bio, Inc. Announces Resignation of Shao-Lee Lin as Class II Director and Chairperson of the Nominating and Governance Committee of the Board

High number of new directors

Third Harmonic Bio Announces Discontinuation of Phase 1B Study of Thb001 in Chronic Inducible Urticaria

We're Not Very Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Rate

Third Harmonic Bio, Inc. has completed an IPO in the amount of $185.3 million.

Third Harmonic Bio, Inc. has completed an IPO in the amount of $185.3 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies